Pfizer Inc., Abbvie Inc., and Bristol-Myers Squibb Company are dominating the Peru Acute Myeloid Leukemia Drugs Market in 2021

Peru Acute Myeloid Leukemia Drugs Market is expected to grow with the CAGR of 6.5% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/peru-acute-myeloid-leukemia-drugs-market

Peru acute myeloid leukemia drugs market is a highly consolidated market. The market has witnessed increased strategic developments owing to favorable market scenarios.

The major players dealing in the acute myeloid leukemia market are introducing strong range of product portfolios. This helped companies to maximize sales with enhanced product portfolio.

Pfizer Inc., is dominating player in the Peru acute myeloid leukemia drugs market. The other key players existing in the market includes are Bristol-Myers Squibb Company, Novartis AG, AbbVie Inc., Merck Sharpe and Dohme, F. Hoffmann-La Roche Ltd, FRESENIUS KABI AG and Others.

Pfizer Inc.

Pfizer Inc. was founded in 1849 and is headquartered in New York, U.S. The company focuses on providing quality standards, safety and value in the discovery, development and manufacturing of healthcare products, including innovative medicines and vaccines. The company offers range of product categories including Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Vaccines, and Anti Infectives in which market focused category fall under oncology. The company is taking strategic initiatives by collaboration.

The company has global presence in North America, Europe, Middle East and Africa, Asia-Pacific and South America and Pfizer Animal Health B.V. (Netherlands), Pfizer Asia International B.V. (Netherlands), Pfizer Australia Superannuation Pty Ltd (Australia), Pfizer Dominicana, S.A. (Dominican Republic) and Pfizer Egypt S.A.E. (Egypt), among others among others are the subsidiary of Merck KGaA.

Abbvie Inc.

Abbvie Inc. was founded in 2013 and is headquartered in Illinois, U.S. The company is a biopharmaceutical company, which specializes in new approaches to addressing today’s health issues, from life-threatening illness to chronic conditions. The company offers range of product categories Immunology, Oncology, Aesthetics, Neuroscience, Eye Care Products, Women’s health Products, Virology, Gastroenterology and Other Specialty Areas and our market focused category is oncology. The company is taking strategic initiatives to increase its product portfolio.

  • In October 2020, AbbVie Inc, had received approval from the U.S. Food and Drug Administration (FDA) for Venclexta, combined with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults, aged 75 years and above. The approval received, had made Abbvie Inc, expand the oncology product line across North America, Latin America and Europe. Venclexta were made available to patients who can’t undergo intensive chemotherapy. Venclexta was also made available for post marketing approval.

The company has global presence in North America, Asia Pacific, South America, Europe, and Latin America. The company has many subsidiaries such Pharmacyclics LLC (Delaware), Allergan Akarna LLC (Delaware), Allergan, Inc. (Delaware), Anterios, Inc. (Delaware) among others.

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, U.S. The company focuses on innovating new solutions in oncology, hematology, immunology and cardiovascular disease by accelerating advancing treatments and improving patients’ therapies. The company offers range of product categories Solid tumors, Hematology, Cardiovascular, Immunology, Fibrotic Diseases, Neuroscience, Translational medicine, Digital health, Cell therapy and Research technologies and our market focused categories are hematology and immunology. The company is taking strategic initiatives to increase its product portfolio.

  • In June 2021, Bristol Myers Squibb had received approval from European Commission for Onureg. Onureg is used as a Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia. The approval received would ensure post marketing approval in the U.S., Europe and South America region. Onureg is expected to increase the sales and product revenue in Peru and Peru, thereby increasing the market growth

The company has global presence in North America, Asia Pacific, South America, Europe, and Latin America. The company has many subsidiaries such as BMS Pharmaceuticals Germany Holdings B.V., BMS Pharmaceuticals International Holdings Netherlands B.V., BMS Pharmaceuticals Korea Holdings B.V., BMS Pharmaceuticals Mexico Holdings B.V., BMS Pharmaceuticals Netherlands Holdings B.V., among others.